Addressing Comorbidities in People with Parkinson’s Disease: Considerations From An Expert Panel
Journal of Parkinson’s Disease · 23.01.2024 · 14 (1) · 53-63
DOI: 10.3233/jpd-230168 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Parkinson’s Disease, online erschienen am 10.01.2024. Verfasst von Camille Carroll und 8 weiteren Autor:innen. Beteiligte Einrichtung: Translational and Clinical Research Institute, Newcastle University, Newcastle, UK. Hauptthemen laut MEDLINE: Parkinson Disease. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
In the UK, guidance exists to aid clinicians and patients deciding when treatment for Parkinson’s disease (PD) should be initiated and which therapies to consider. National Institute for Health and Care Excellence (NICE) guidance recommends that before starting PD treatment clinicians should discuss the following: the patient’s individual clinical circumstances; lifestyle; preferences; needs and goals; as well as the potential benefits and harms of the different drug classes. Individualization of medicines and management in PD significantly improves patients’ outcomes and quality of life. This article aims to provide simple and practical guidance to help clinicians address common, but often overlooked, co-morbidities. A multi-disciplinary group of PD experts discussed areas where clinical care can be improved by addressing commonly found co-morbidities in people with Parkinson’s (PwP) based on clinical experience and existing literature, in a roundtable meeting organized and funded by Bial Pharma UK Ltd. The experts identified four core areas (bone health, cardiovascular risk, anticholinergic burden, and sleep quality) that, if further standardized may improve treatment outcomes for PwP patients. Focusing on anticholinergic burden, cardiac risk, sleep, and bone health could offer a significant contribution to personalizing regimes for PwP and improving overall patient outcomes. Within this opinion-based paper, the experts offer a list of guiding factors to help practitioners in the management of PwP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational and Clinical Research Institute, Newcastle University, Newcastle, UK.
- University of Plymouth and University Hospitals Plymouth NHS Trust, Plymouth, UK.
- University of Birmingham and City Hospital, Birmingham, UK.
- University of Glasgow, Glasgow, UK.
- University College London Hospitals, London, UK.
- Cardiff and Vale University Health Board, Cardiff, UK.
Zitieren
APA
Carroll, C., Clarke, C. E., Grosset, D., Rather, A., Mohamed, B., Parry, M., Reddy, P., Fackrell, R., & Chaudhuri, K. R. (2024). Addressing Comorbidities in People with Parkinson’s Disease: Considerations From An Expert Panel. Journal of Parkinson’s Disease, 14(1), 53-63. https://doi.org/10.3233/jpd-230168
Vancouver
Carroll C, Clarke CE, Grosset D, Rather A, Mohamed B, Parry M, et al. Addressing Comorbidities in People with Parkinson’s Disease: Considerations From An Expert Panel. Journal of Parkinson’s Disease. 2024;14(1):53-63. doi:10.3233/jpd-230168
BibTeX
@article{Carroll2024,
author = {Carroll, Camille and Clarke, Carl E and Grosset, Donald and Rather, Arshad and Mohamed, Biju and Parry, Miriam and Reddy, Prashanth and Fackrell, Robin and Chaudhuri, Kallol Ray},
title = {Addressing Comorbidities in People with Parkinson’s Disease: Considerations From An Expert Panel},
journal = {Journal of Parkinson’s Disease},
year = {2024},
volume = {14},
number = {1},
pages = {53--63},
doi = {10.3233/jpd-230168}
}
EUVIMED